InnovoTEX is developing its TEX CORE platform for compounds that are tumor-localizing, well-tolerated, and use a multi-modal design for multiple solid tumor indications.
OxaliTEX-Pt(IV) is the first product candidate being developed from the TEX CORE platform. Initial indication is platinum-resistant ovarian cancer.
AuraTEX is a novel gold-based therapy that can both eradicate cancer and stimulate an anti-cancer immune response.
Industry insights and educational resources.
This website contains forward-looking statements and projections based on current expectations about future events, derived from information currently available. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements contained in this website speak only as of the date hereof and the presenter undertakes no obligation to correct or update any forward-looking statement. No assurances can be given that the Company’s results will be as projected in this presentation. This website is not an offering of securities. Any offering will be made solely pursuant to formal offering documents.